Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.
Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS. Mathew SJ, et al. Among authors: bani ms. Eur Neuropsychopharmacol. 2011 Mar;21(3):221-9. doi: 10.1016/j.euroneuro.2010.11.012. Epub 2010 Dec 30. Eur Neuropsychopharmacol. 2011. PMID: 21194898 Free PMC article. Clinical Trial.
A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety.
Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, Pissiota A, Frans O, Bani M, Bettica P, Pich EM, Jacobsson E, Wahlstedt K, Oreland L, Långström B, Eriksson E, Fredrikson M. Furmark T, et al. J Neurosci. 2008 Dec 3;28(49):13066-74. doi: 10.1523/JNEUROSCI.2534-08.2008. J Neurosci. 2008. PMID: 19052197 Free PMC article. Clinical Trial.
Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery.
Giménez M, Ortiz H, Soriano-Mas C, López-Solà M, Farré M, Deus J, Martín-Santos R, Fernandes S, Fina P, Bani M, Zancan S, Pujol J, Merlo-Pich E. Giménez M, et al. Eur Neuropsychopharmacol. 2014 Jan;24(1):105-16. doi: 10.1016/j.euroneuro.2013.09.004. Epub 2013 Oct 14. Eur Neuropsychopharmacol. 2014. PMID: 24332890 Clinical Trial.
The effects of the dopamine D₃ receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects.
Nathan PJ, O'Neill BV, Mogg K, Bradley BP, Beaver J, Bani M, Merlo-Pich E, Fletcher PC, Swirski B, Koch A, Dodds CM, Bullmore ET. Nathan PJ, et al. Int J Neuropsychopharmacol. 2012 Mar;15(2):149-61. doi: 10.1017/S1461145711001052. Epub 2011 Jul 12. Int J Neuropsychopharmacol. 2012. PMID: 21745436 Free article. Clinical Trial.
In vivo imaging of cerebral dopamine D3 receptors in alcoholism.
Erritzoe D, Tziortzi A, Bargiela D, Colasanti A, Searle GE, Gunn RN, Beaver JD, Waldman A, Nutt DJ, Bani M, Merlo-Pich E, Rabiner EA, Lingford-Hughes A. Erritzoe D, et al. Neuropsychopharmacology. 2014 Jun;39(7):1703-12. doi: 10.1038/npp.2014.18. Epub 2014 Jan 28. Neuropsychopharmacology. 2014. PMID: 24469594 Free PMC article.
43 results